MEDIMMUNE, INSERM AND INSERM TRANSFERT ANNOUNCE STRATEGIC COLLABORATION TO FUND AND CONDUCT MEDICAL SCIENCE RESEARCH
GAITHERSBURG, MD and PARIS, March 30, 2011 – MedImmune, the global biologics business of AstraZeneca, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), today announced a three-year strategic collaboration to advance research across a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. Research will explore translational biology and new disease mechanisms, as well as evaluate potential drug candidates.
The collaboration calls for MedImmune funding and joint scientific collaboration commencing with 10 research projects, maximizing Inserm’s unique capability to conduct research by blended physician/biologist teams, and their unparalleled link to patient populations and understanding of human diseases. Additional research projects are being evaluated.